Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of obeticholic acid on hepatic metabolism and detoxification in morbidly obese and gallstone patients
2011-000813-37Phase 2Completed
- Sponsor
- Sahlgrenska Academy
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of obeticholic acid in metabolic dysfunction-associated steatotic liver disease (MASLD), steatosis, class III obesity and 1 more, sponsored by Sahlgrenska Academy. Primary endpoint: Relative changes in markers for insulin resistance. Started Mar 2011; status: completed.
02
Drugs
obeticholic acid
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)steatosisclass III obesitycholelithiasis
Beyond the preview
Go deeper on 2011-000813-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000813-37.